Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study June 2025 Congress News Read more
2021 November Clinical trials New insights in clinical outcomes of patients with ALL and Down Syndrome Read more
2021 November Clinical practice DEFINING LOW-RISK HIGH HYPERDIPLOIDY IN PAEDIATRIC PATIENTS WITH ALL Read more
2021 November Clinical practice CAR-T therapy bridged to haplo-HSCT improves survival of children with R/R B-ALL Read more
2021 November Clinical trials CD19-targeted CAR-T therapy for CNS relapsed or refractory ALL Read more
2021 November Science Autologous CAT19-41BB-Z CAR-T cells as a stand-alone treatment for R/R adult B-ALL Read more
2021 October Editor's pick RELEVANT LITERATURE FOR YOUR DAILY PRACTICE SELECTED BY: GREGOR VERHOEF Read more
Top
